The analysis was performed on a cohort of 101 advanced NSCLC patients either carrying an activating EGFR gene mutation or with unknown EGFR gene status but with potential benefit from EGFR‐TKIs.12 All patients received standard first‐line administration of gefitinib, erlotinib, and icotinib without any chemotherapy or localized treatment. Here, EGFR is linked to non-small cell lung carcinoma.